Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1985 1
1989 2
1995 1
1996 2
1997 1
2001 4
2002 1
2003 1
2004 3
2005 5
2006 4
2007 2
2008 2
2009 6
2010 11
2011 7
2012 12
2013 9
2014 8
2015 16
2016 8
2017 17
2018 2
2019 7
2020 4
2021 9
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

138 results
Results by year
Filters applied: . Clear all
Page 1
A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
Hartley A, Kavishwar G, Salvato I, Marchini A. Hartley A, et al. Annu Rev Virol. 2020 Sep 29;7(1):537-557. doi: 10.1146/annurev-virology-012220-023606. Epub 2020 Jun 29. Annu Rev Virol. 2020. PMID: 32600158 Review.
Various strategies have been employed to improve the anticancer activities of oncolytic PVs, including development of second-generation parvoviruses with enhanced oncolytic and immunostimulatory activities and rational combination of PVs with other therapies. …
Various strategies have been employed to improve the anticancer activities of oncolytic PVs, including development of second-generati …
Canine Parvovirus and Its Non-Structural Gene 1 as Oncolytic Agents: Mechanism of Action and Induction of Anti-Tumor Immune Response.
Arora R, Malla WA, Tyagi A, Mahajan S, Sajjanar B, Tiwari AK. Arora R, et al. Front Oncol. 2021 May 3;11:648873. doi: 10.3389/fonc.2021.648873. eCollection 2021. Front Oncol. 2021. PMID: 34012915 Free PMC article. Review.
Canine parvovirus (CPV) is an oncolytic virus that specifically targets and kills cancer cells by causing DNA damage, caspase activation, and mitochondrial damage. Non-structural gene 1 (NS1) of CPV, involved in viral DNA replication is a key mediator of cytotoxicit …
Canine parvovirus (CPV) is an oncolytic virus that specifically targets and kills cancer cells by causing DNA damage, caspase …
Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
Ferreira T, Kulkarni A, Bretscher C, Richter K, Ehrlich M, Marchini A. Ferreira T, et al. Viruses. 2020 Oct 21;12(10):1199. doi: 10.3390/v12101199. Viruses. 2020. PMID: 33096814 Free PMC article.
H-1 protoparvovirus (H-1PV) is a self-propagating virus that is non-pathogenic in humans and has oncolytic and oncosuppressive activities. H-1PV is the first member of the Parvoviridae family to undergo clinical testing as an anticancer agent. ...This is the first study th …
H-1 protoparvovirus (H-1PV) is a self-propagating virus that is non-pathogenic in humans and has oncolytic and oncosuppressive activi …
Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
Kulkarni A, Ferreira T, Bretscher C, Grewenig A, El-Andaloussi N, Bonifati S, Marttila T, Palissot V, Hossain JA, Azuaje F, Miletic H, Ystaas LAR, Golebiewska A, Niclou SP, Roeth R, Niesler B, Weiss A, Brino L, Marchini A. Kulkarni A, et al. Nat Commun. 2021 Jun 22;12(1):3834. doi: 10.1038/s41467-021-24034-7. Nat Commun. 2021. PMID: 34158478 Free PMC article.
H-1 parvovirus (H-1PV) is a promising anticancer therapy. However, in-depth understanding of its life cycle, including the host cell factors needed for infectivity and oncolysis, is lacking. ...We also provide evidence of a direct correlation between LAMC1 expression level …
H-1 parvovirus (H-1PV) is a promising anticancer therapy. However, in-depth understanding of its life cycle, including the host cell …
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR, Rommelaere J. Moehler M, et al. Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092. eCollection 2014. Front Oncol. 2014. PMID: 24822170 Free PMC article. Review.
By generating tumor cell lysates in situ, oncolytic viruses overcome cellular tumor resistance mechanisms and induce immunogenic tumor cell death resulting in the recognition of newly released tumor antigens. This is in particular the case of the oncolytic parvov
By generating tumor cell lysates in situ, oncolytic viruses overcome cellular tumor resistance mechanisms and induce immunogenic tumo …
New Insights into Parvovirus Research.
Gallinella G. Gallinella G. Viruses. 2019 Nov 13;11(11):1053. doi: 10.3390/v11111053. Viruses. 2019. PMID: 31766142 Free PMC article.
The Special Issue of 'Viruses' dedicated to the 'New Insights into Parvovirus Research' aimed at presenting a 'state of the art' in many aspects of research in the field, at collecting the newest contributions on unresolved issues, and at presenting new approaches exploiti …
The Special Issue of 'Viruses' dedicated to the 'New Insights into Parvovirus Research' aimed at presenting a 'state of the art' in m …
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
Hajda J, Leuchs B, Angelova AL, Frehtman V, Rommelaere J, Mertens M, Pilz M, Kieser M, Krebs O, Dahm M, Huber B, Engeland CE, Mavratzas A, Hohmann N, Schreiber J, Jäger D, Halama N, Sedlaczek O, Gaida MM, Daniel V, Springfeld C, Ungerechts G. Hajda J, et al. Clin Cancer Res. 2021 Oct 15;27(20):5546-5556. doi: 10.1158/1078-0432.CCR-21-1020. Epub 2021 Aug 23. Clin Cancer Res. 2021. PMID: 34426438 Clinical Trial.
PURPOSE: To investigate the safety, clinical efficacy, virus pharmacokinetics, shedding, and immune response after administration of an oncolytic parvovirus (H-1PV, ParvOryx) to patients with metastatic pancreatic ductal adenocarcinoma (PDAC) refractory to first-lin …
PURPOSE: To investigate the safety, clinical efficacy, virus pharmacokinetics, shedding, and immune response after administration of an o
Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells.
Ferreira T, Kulkarni A, Bretscher C, Nazarov PV, Hossain JA, Ystaas LAR, Miletic H, Röth R, Niesler B, Marchini A. Ferreira T, et al. Viruses. 2022 May 11;14(5):1018. doi: 10.3390/v14051018. Viruses. 2022. PMID: 35632759 Free PMC article.
We also find a direct correlation between LGALS1 transcript levels and H-1PV oncolytic activity in 53 cancer cell lines from different tumour origins. ...
We also find a direct correlation between LGALS1 transcript levels and H-1PV oncolytic activity in 53 cancer cell lines from differen …
Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer.
Neulinger-Muñoz M, Schaack D, Grekova SP, Bauer AS, Giese T, Salg GA, Espinet E, Leuchs B, Heller A, Nüesch JPF, Schenk M, Volkmar M, Giese NA. Neulinger-Muñoz M, et al. Viruses. 2021 May 28;13(6):1019. doi: 10.3390/v13061019. Viruses. 2021. PMID: 34071585 Free PMC article.
Although the oncolytic parvovirus H-1PV has entered clinical trials, predicting therapeutic success remains challenging. We investigated whether the antiviral state in tumor cells determines the parvoviral oncolytic efficacy. The interferon/interferon-stimula …
Although the oncolytic parvovirus H-1PV has entered clinical trials, predicting therapeutic success remains challenging. We in …
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM, Friedman GK, Cassady KA, Markert JM. Foreman PM, et al. Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Neurotherapeutics. 2017. PMID: 28265902 Free PMC article. Review.
The concept of virotherapy for the treatment of malignant tumors dates back more than a century and can be divided into replication-competent oncolytic viruses and replication-deficient viral vectors. Oncolytic viruses are designed to selectively target, infect, and …
The concept of virotherapy for the treatment of malignant tumors dates back more than a century and can be divided into replication-competen …
138 results